Thromb Haemost 1962; 07(01): 016-026
DOI: 10.1055/s-0038-1655452
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Effects of Certain Phospholipids on Plasminogen Activation and Plasmin Activity[*]

Claire Gerbeck
1   Coagulation Research Laboratory, Department of Surgery, Presbyterian-St. Luke’s Hospital, affiliated with the College of Medicine, University of Illinois, Chicago
,
J. L Koppel
1   Coagulation Research Laboratory, Department of Surgery, Presbyterian-St. Luke’s Hospital, affiliated with the College of Medicine, University of Illinois, Chicago
,
John H Olwin
1   Coagulation Research Laboratory, Department of Surgery, Presbyterian-St. Luke’s Hospital, affiliated with the College of Medicine, University of Illinois, Chicago
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2018 (online)

Summary

Crude and partially purified phospholipid preparations have been studied for their effects on a) the activation of purified human plasminogen by streptokinase and b) the activity of plasmin resulting from such activation. Plasmin activity has been measured as BAMe esterase, caseinolytic, and fibrinolytic activities.

Plasmin BAMe esterase activity was significantly enhanced by phosphatidyl inositol and phosphatidyl serine but only slightly by phosphatidyl ethanolamine. Preparations of asolectin and cephalin, although not having any effect on plasmin BAMe esterase activity per se, did appear to increase plasminogen activation by streptokinase. None of the above-mentioned effects was observed when plasmin caseinolytic activity was measured. The phospholipid preparation having the greatest effect on plasmin BAMe esterase activity, phosphatidyl inositol, also exhibited an effect on plasmin fibrinolytic activity. With both BAMe esterase and fibrinolytic activities the effects produced by the phospholipid materials were concentration dependent and, in the case of fibrinolytic activity, increased concentrations beyond the optimum level resulted in a gradual diminution in activity and eventual inhibition.

* The investigations in this field carried on in the Coagulation Research Laboratory, Presbyterian-St. Luke’s Hospital were supported by the Medical Research and Development Board, Office of the Surgeon General, Department of the Army, under Contract No. DA-49-007-MD-275 and by the National Heart Institute, National Institutes of Health, under grant H-3940.